Follow-Up of Parametric Maps of the Tumoral Perfusion in Patients with Treated Bone Metastases of Prostate Cancer.

Nicolas Michoux¹, Bertrand Tombal², Jean-Pascal Machiels³, Frederic Lecouvet¹

Using dynamic contrast-enhanced magnetic resonance imaging with a pharmacokinetic modeling of the data, the monitoring of the effects of anti-cancer therapy on bone metastases of prostate cancer during the course of the therapy becomes feasible. Ten patients scheduled to receive hormonotherapy or Taxotere therapy were imaged on a 1.5T MR scanner within one week before, 7 and 30 days after initial treatment. Perfusion maps based on Ktrans, ve and vp parameters were reconstructed. Complex changes reflecting either a decrease with a homogenization of the perfusion or an increase with a heterogenization of the perfusion, were observed in responders to therapy.